SecBot SecBot

HCM drug pipeline

HUTCHMED (China) Ltd · 3 rated drugs
$14.73
−1.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 bullish · 1 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhaseApproved in China (3 indications); global Phase 3 readout pending
Time to marketAlready approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.

ORPATHYS savolitinib Updated Aug 2

What to watch

Watch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.

Bull case
  • Third China approval (July 2026) for MET-amplified gastric cancer, a first-in-class claim in that setting, supported by 32.3% ORR / 4.0-month median PFS in a pivotal Phase 2 (per HUTCHMED 6-K filed 2026-07-02)
  • Commercial traction: H1 2026 Oncology/Immunology marketed-product revenue up 23% to $121.4M, and ORPATHYS is already NRDL-reimbursed in China (since March 2023) for lung cancer, per H1 2026 6-K (filed 2026-07-30)
  • SAFFRON global Phase 3 + SANOVO China Phase 3 topline readouts guided to H2 2026, positive results could support US/EU filings via partner AstraZeneca
Bear case
  • Gastric approval is CONDITIONAL, post-marketing confirmatory data are required; failure could restrict the label
  • MET-amplified gastric cancer is a small niche (~18,000 patients/yr in China, ~4-6% of gastric cases) limiting the new indication's revenue ceiling
  • SAFFRON/SANOVO Phase 3 readouts in H2 2026 are binary, a miss or delay stalls the ex-China expansion thesis; HUTCHMED's own risk section flags trials 'may miss endpoints'
▲ bullish
Impact
PhaseApproved / marketed
Time to marketAlready commercialized — approved and selling in China as ELUNATE, and ex-US as FRUZAQLA (approved/launched in 41 countries per H1 2026 results).

ELUNATE fruquintinib Updated Aug 2

What to watch

For HCM investors, ELUNATE is a maturing growth product (in-market sales +41% to $60.8M in H1 2026) whose main watch-item is whether the new RCC indication gains NRDL reimbursement and accelerates China uptake; the share-price-moving binaries in the next ~6 months (savolitinib SAFFRON/SANOVO readouts, sovleplenib NDA decisions) are other drugs, so don't buy HCM expecting an ELUNATE-specific catalyst.

Bull case
  • New indication: NMPA approved ELUNATE + sintilimab for 2nd-line advanced/metastatic RCC in China (May 21, 2026), based on FRUSICA-2 showing a 63% reduction in risk of disease progression or death and median PFS of 22.2 months vs 6.9 months for the control arm (HUTCHMED 6-K / company announcement).
  • Commercial momentum: H1 2026 ELUNATE in-market sales grew 41% to $60.8M, leading the company's China product recovery (H1 2026 interim results / 6-K).
  • International optionality: the same molecule marketed ex-US as FRUZAQLA grew in-market sales 70% to $68.9M in H1 2026 and is approved/launched in 41 countries (H1 2026 6-K).
Bear case
  • No near-term binary for this drug: it is already approved and selling, and its last hard catalyst (RCC NMPA approval) passed in May 2026, the stock's next scheduled catalysts (savolitinib SAFFRON/SANOVO Phase 3 readouts, H2 2026) are a different molecule (H1 2026 6-K).
  • China pricing/payer risk: HUTCHMED's own filing analysis flags an uncertain China regulatory and pricing/reimbursement environment, with NRDL (national reimbursement list) renewals a potential margin pressure point (6-K risk list).
  • Competition: the 6-K risk list explicitly cites competition in CRC (FRUZAQLA) from newer therapies, CRC is the foundational indication of this molecule.
● neutral
Impact
PhaseApproved (China) and commercially marketed; ongoing Phase 2 academic combination studies elsewhere
Time to marketAlready approved and marketed in China (Sulanda); no US/EU filing appears in the active pipeline, and no FDA action or catalyst records exist in the ingested data.

SULANDA surufatinib Updated Aug 2

What to watch

Sulanda is a commercial revenue contributor, not a binary catalyst: H1 2026 in-market sales grew ~45% to $18.4M, but the next big HCM stock movers (savolitinib SAFFRON/SANOVO Phase III readouts expected H2 2026, two sovleplenib NDA decisions in China) are different drugs. Watch China NRDL/pricing news and NET competition for Sulanda-specific pressure; watch SAFFRON/SANOVO and sovleplenib for the actual share-price catalysts.

Bull case
  • Already approved and commercialized in China, no development or approval risk remaining; it is generating real revenue today (H1 2026 in-market sales $18.4M, +45% YoY per HUTCHMED's interim-results 6-K analysis).
  • Sulanda is a growth leader in HUTCHMED's China commercial recovery, alongside Elunate (+41%) and Fruzaqla ex-US (+70%), inside a 23% YoY increase in Oncology/Immunology product revenue to $121.4M.
  • Ongoing combination studies in GI/pancreatic cancers (updated data presented at AACR 2026 per company press release) add pipeline optionality on top of the commercial base.
Bear case
  • No hard, dated binary catalyst for Sulanda in the next ~12 months, an approved drug with no pending PDUFA/readout can only drive modest, sales-driven moves; the stock's real binaries (SAFFRON/SANOVO Phase III H2 2026, sovleplenib NDAs) are other programs.
  • Small share of value: $18.4M of H1 2026 in-market sales versus $121.4M total Oncology/Immunology product revenue and a ~$1.99B market cap, even a big Sulanda swing moves HCM only slightly.
  • China-only commercial footprint with the company's own risk list flagging NET competition from newer therapies and an uncertain NRDL/pricing/payer environment that could pressure margins.